Clinical evaluation of flutropium bromide in nasal hypersensitivity

A comparative study of flutropium bromide alone and in combination with an antiallergic agent conducted at 24 institutions in the Kyushu area

Abstract

Twenty-four Kyushu area institutions participated in a clinical study of Flutropium Bromide (Flubron). Ninety-six patients with allergic rhinitis and 20 patients with vasomotor rhinitis were enrolled and divided into two groups. One group received Flubron alone, the other received Flubron combined with an antiallergic agent. After two weeks, 80.4% of patients given Flubron alone, and 81.3% of the patients given the combination drugs reported responses of “slightly improved” and “better.” The rates of effectiveness were not statistically significant, however, the patients receiving Flubron alone showed less symptoms clinically than the combined-drug group. Slight side effects were reported in four patients, two receiving Flubron alone, and two receiving the combination of drugs. Based on these results, it was concluded that Flubron alone or Flubron combined with antiallergic agents can effectively treat patients with allergic or vasomotor rhinitis, without adverse effects.